Monoclonal antibodies to target epidermal growth factor receptor–positive tumors

TLDR

Traditional cytotoxic therapies for cancer have limited efficacy and high toxicity, and about 30 % of human tumors overexpress EGFR, a marker linked to poorer prognosis, prompting the development of anti‑EGFR monoclonal antibodies currently in clinical trials. The study aims to evaluate EGFR blockade via monoclonal antibodies as a non‑cytotoxic alternative to treat human tumors. Anti‑EGFR monoclonal antibodies competitively inhibit EGF and TGF‑α binding, block downstream signaling, and suppress tumor growth, with agents such as IMC‑C225, EMD 55900, ICR 62, and ABX‑EGF showing promising efficacy and tolerability in preclinical studies. EGFR‑targeted therapy meets unmet needs for EGFR‑positive epithelial cancers such as head and neck, lung, and colon malignancies.

Abstract

Traditional cytotoxic approaches to tumor management are associated with efficacy and toxicity limitations. Blockade of the epidermal growth factor receptor (EGFR) and its ligands is a novel approach to the treatment of human tumors that offers a noncytotoxic alternative to cancer treatment.An English-language literature search was conducted to identify studies assessing the in vitro and in vivo effects of EGFR blockade with an emphasis on approaches that use monoclonal antibody therapy.The EGF pathway regulates normal cellular processes and appears to be correlated with the development of malignancy. Approximately 30% of human tumors express EGFR, which has been reported to be correlated with poor prognosis and diminished disease-free and overall survival in selected tumor types. A number of anti-EGFR monoclonal antibodies have been developed, which currently are undergoing clinical trials in humans. Effective anti-EGFR monoclonal antibodies compete with endogenous ligands, primarily EGF and transforming growth factor-alpha, for receptor ligand-binding sites. Binding to EGFR blocks critical signaling pathways and interferes with the growth of tumors expressing EGFR. Anti-EGFR monoclonal antibodies that currently are under study include IMC-C225, EMD 55900, ICR 62, and ABX-EGF.These antibodies have demonstrated promising results and appear to have been well tolerated. EGFR-targeted therapy addresses important, unmet needs in the treatment of human tumors, particularly EGFR-positive epithelial tumors including common malignancies of the head and neck, lung, and colon.